Skip to main content
OpenTrials
Completed

NCT Number: NCT04154722

Comparison of Two Drugs Regimen in Treatment of Complicated Typhoid Fever in Children

This study evaluates whether XDR Typhoid fever in children can be effectively treated with monotherapy (meropenum alone), or a combination (meropenum and azithromycin).

Completed

Looking for future studies?

Notify Me

Key information

Age range

6 month–18 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Ziauddin University

Karachi, Sindh, 75600, Pakistan

About this study

Complicated XDR Enteric fever is a very serious systemic disease, caused by an extremely resistant mutant strain of Salmonella Typhi ( the H58 S. Typhi superbug,) that as the name suggests is resistant to not only the first but also the second tier drugs conventionally used for treatment of the same. And as such, warrants immediate antibiotic therapy, but in view of the extended antimicrobial resistance the treatment options are limited to only two effective drugs viz Carbepenem and Azithromycin, as per culture sensitivity.

So far, in the absence of universal standardized treatment protocols for XDR complicated typhoid fever in children, random use of either one or both in combination is the current practice.

However, keeping antibiotic stewardship in mind, it is imperative to ascertain whether meropenum alone is effective or should be combined with azithromycin in the treatment of this serious disease.

Our study therefore compares the efficacy of monotherapy with meropenum or combination with azithromycin based on clinical and microbiologic remission, shortened hospital stay and less chances of relapse in order to then formulate a standardized protocol to treat complicated XDR typhoid in children thus preventing yet further antimicrobial resistance.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients with extended drug resistant typhoid fever defined as culture proven typhoid fever caused by Salmonella Typhi or Para typhi resistant to Ampicillin, Chloramphenicol,Co trimoxazole,Quinolones and Ceftriaxone along with two or more of the following condition

  • High grade fever spikes for more than three days
  • Refusal to eat or drink
  • Drowsy or Unconscious
  • Convulsions
  • Dehydration due to diarrhea or vomiting
  • Abdominal distension with or without tenderness
  • Bleeding diathesis like petechial rash, gum bleed, melena
  • Jaundice or alanine transaminase more than twice of the normal range
  • Thrombocytopenia less than fifty thousand
  • Increase Prothrombin time and activated partial thromboplastin time
  • Electrolyte imbalance like hyponatremia, hypernatremia, hypokalemia, hyperkalemia, metabolic acidosis
  • Hypoglycemia
  • Signs of shock like cold and mottled skin, feeble pulses, tachycardia, decreased blood pressure

Exclusion criteria

  • Not given informed consent
  • Children who need ventilator or two inotrope support
  • Severe malnutrition/immunocompromised patient

Treatment and study plan

Meropenem Injection

Drug

inj meropenum for 10 days

Other names: meroneum, penro

Azithromycin Powder

Drug

syp azithromycin for10days

Other names: azomax, zetro

Primary outcomes

  1. clinical clearance

    Time frame: 10 days

    improvement of the signs and symptoms as given in the operational definition

Secondary outcomes

  1. bacterial clearance

    Time frame: 5 days

    negative blood cultures

Other outcomes

  1. relapse of typhoid fever

    Time frame: 15 days after completing treatment

    reappearance of the signs and symptoms of typhoid fever along with positive blood cultures

Sponsors and collaborators

Lead sponsor

Ziauddin University

Other

Registry information

Official study title

Treatment of 21st Century Typhoid Fever in Children;Open Label Mono vs Combination Drug Therapy

Acronym: [XDRTYPHOID]

Important dates

Study start
2019
Primary completion
2020
Study completion
2020
First posted
Nov 6, 2019
Registry last updated
Jun 16, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.